Mary Kay Inspires Beauty Trends at Spring/Summer 2020 Fashion Weeks in Europe
Mary Kay Inc. continues to make its mark on the beauty industry through its ongoing partnerships with Ukrainian and Belarus Fashion Weeks, Mercedes-Benz Fashion Week Russia, and Bratislava Fashion Days in Slovakia and Czech Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005838/en/
Mercedes-Benz Fashion Week Russia (Photo: Mary Kay Inc.)
“As an innovator of beauty trends, Mary Kay along with beauty artists, unveiled 2020 runway looks throughout fashion weeks in Europe,” stated Tara Eustace, President of Mary Kay for the European Region. “The runways at fashion week are the perfect stage to share inspiration, debut our innovations with the fashion world and elevate makeup trends in each of these countries.”
Designers, influencers, celebrities, makeup artists, beauty bloggers and editors attended all five events where Mary Kay was the official beauty partner for the spring/summer 2020 fashion week season.
“The Mary Kay Global Design Studio was created over 10 years ago to inspire beauty trends and drive innovation, fueling creativity and individuality through fashion collaborations around the world,” said Sheryl Adkins-Green, Chief Marketing Officer, and Creative & Inspiration Officer for the Mary Kay Global Design Studio. “During fashion weeks, makeup artists in collaboration with Mary Kay, unleashed some of the major trends of the season. Beauty enthusiasts can get the look ‘as seen’ on the runway or revisit the inspiration to create their own.”
Fashion Weeks Highlights:
Held in Kyiv between August 31-September 4, 2019, Ukrainian Fashion Week (UFW) kicked off the Mary Kay sponsored events in Europe. Under the artistic direction of lead makeup artist MartElle, a team of 40 beauty artists, all of whom are also members of the Mary Kay independent sales force, prepped the runway models for 30 Ukrainian designers and performed 350 different makeup looks throughout UFW. One of the fashion shows was an exclusive capsule pink bra collection collaboration between Mary Kay Ukraine and lingerie brand Keòsme aimed at supporting women diagnosed with breast cancer. Ten percent of sales proceeds from the exclusive collection will be donated to a Ukrainian nonprofit organization that promotes female health and wellness.
Bratislava Fashion Days by Mercedes-Benz was next in Bratislava on September 16-19, and Prague on October 5-6. For the second year in a row, Mary Kay Slovakia was the Official Makeup Artist for the event. Makeup artists prepared the show-stopping makeup looks worn by runway models and starred in the backstage stories on Fashion TV. Inspired by Mary Kay’s Global Beauty Ambassador Luis Casco, the “Sparkling Pewter,” “Sultry Glam,” “Sweet Champagne,” and “Garnet Gold” special looks became the highlights of the shows. The December 17 show in Bratislava marked the closing of the 2019 edition of the Fashion Days.
Mary Kay Russia has been the Official Makeup Artist of the Mercedes-Benz Fashion Week Russia (MBFW Russia) for 7 years in a row—13 consecutive seasons. The largest fashion event in Eastern Europe, MBFW Russia was held in Moscow on October 15-19. Luis Casco, and star makeup artist Andrey Shilkov, co-created the looks for 109 shows out of a total of 119, while a makeup team from the Mary Kay Russia independent sales force represented the brand backstage. The stunning beauty look imagined for the Te Amo Couture runway show was the result of the exclusive Casco-Shilkov collaboration.
The Belarus Fashion Week (BFW) held in Minsk on October 17- 20, 2019, wrapped up a successful fashion week season for Mary Kay in Eastern Europe. Mary Kay was BFW Official Makeup Artist for the 7th season in a row. A team of beauty artists from the Mary Kay Belarus independent sales force featured 650 runway looks and no less than 500 makeovers under the guidance of beauty artist maestro Alexander Kiryniuk, who also presented the season's trends.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005838/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom